Latanoprost Viatris

Latanoprost, the active ingredient in Latanoprost Viatris, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension, helping to preserve visual function. The medication is administered as a single drop in the affected eye(s) once daily, typically in the evening, to achieve consistent pressure control.

GNH USA supplies Latanoprost Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used in ocular hypotensive therapy to manage elevated eye pressure. Open-angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers eye pressure to prevent conversion to glaucoma.

Latanoprost may cause ocular and systemic reactions; reported events are categorized by frequency. Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Iris darkening: gradual increase in brown pigmentation. - Eyelash growth: longer, thicker lashes. - Eye irritation: foreign body sensation or mild discomfort. Serious or Rare Side Effects: - Uveitis: inflammation of the uveal tract requiring medical attention. - Allergic reaction: swelling, itching, or rash around the eye. - Severe eye pain: may indicate corneal involvement. - Vision loss: rare but possible if intra‑ocular pressure drops excessively.

When prescribing Latanoprost, clinicians should consider several safety measures. Monitor intra‑ocular pressure: assess response after initiation. Assess for ocular allergies: discontinue if severe irritation occurs. Avoid use in active eye infection: may exacerbate condition. Inform patients about possible iris color change: usually permanent. Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ophthalmic agents; awareness of interaction severity guides clinical decisions. Major Interactions (Avoid): - Concurrent use with other prostaglandin analogs: additive ocular side effects and hyperpigmentation. - Combination with systemic carbonic anhydrase inhibitors: excessive intra‑ocular pressure reduction may lead to hypotony. Moderate Interactions (Monitor Closely): - Co‑administration with topical non‑steroidal anti‑inflammatory drugs (NSAIDs): may diminish latanoprost efficacy. - Use with beta‑blocker eye drops (e.g., timolol): monitor for enhanced pressure‑lowering effect. - Interaction with ocular anesthetics: possible increased ocular discomfort.